Pradhan, Jaya Prakash (2006): Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies.
Download (993kB) | Preview
What are the trends in the global competitiveness of the Indian pharmaceutical industry? Where does this industry stand when compared to global peers on pharmaceutical value-added, productivity, research and development and trade performance? What are the new strategies that Indian pharmaceutical companies are adopting to become global players? These questions are addressed in this paper. It is found that strategic government policies were the main factors that transformed the status of the Indian pharmaceutical industry from a mere importer and distributor of drugs and pharmaceuticals to an innovation-driven cost-effective producer of quality drugs. India emerged as one of the fast growing pharmaceutical industry in the world with growing trade surpluses and exports. However, there are certain limitations that the government policies need to address, like low productivity and R&D intensity. A host of competitive strategies, like greenfield direct investment, overseas acquisitions, strategic alliances and contract manufacturing have emerged as favourites to Indian pharmaceutical firms recently.
|Item Type:||MPRA Paper|
|Original Title:||Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies|
|Keywords:||Indian Pharmaceutical Industry; Productivity; Innovation; Trade; Strategic Alliances; Foreign Investment; M&As|
|Subjects:||L - Industrial Organization > L6 - Industry Studies: Manufacturing > L65 - Chemicals; Rubber; Drugs; Biotechnology
O - Economic Development, Technological Change, and Growth > O3 - Technological Change; Research and Development; Intellectual Property Rights > O30 - General
L - Industrial Organization > L2 - Firm Objectives, Organization, and Behavior > L20 - General
F - International Economics > F1 - Trade > F14 - Empirical Studies of Trade
G - Financial Economics > G3 - Corporate Finance and Governance > G34 - Mergers; Acquisitions; Restructuring; Corporate Governance
L - Industrial Organization > L2 - Firm Objectives, Organization, and Behavior > L22 - Firm Organization and Market Structure
D - Microeconomics > D2 - Production and Organizations > D24 - Production; Cost; Capital; Capital, Total Factor, and Multifactor Productivity; Capacity
|Depositing User:||Jaya Prakash Pradhan|
|Date Deposited:||23. Dec 2008 13:24|
|Last Modified:||16. Feb 2013 16:48|
Ajanta Pharma (2005), Annual Report 2004–05.
Associated Press (2006), ‘Ranbaxy Laboratories to Acquire Terapia’, March 29.
Business Journal of Jacksonville (2006), ‘Ranbaxy buys patents for autoinjector device’, March 21.
Business Line (2002), ‘Core Healthcare IV fluid bottle output at 1 billion’, Friday, Aug 16.
Business Line (2002), ‘Core Healthcare IV fluid bottle output at 1 billion’, Friday, Aug 16.
Business World (2004), ‘PHARMA M&AS: What's the big deal?’, June 28.
Business World (2006), ‘Sun Pharma: Mr Conservative gets it right’, January 30.
Deccan Herald (2005), ‘Drug patent: A Viagra for Indian pharmaceutical industry’, April 4.
Department of Chemicals and Petrochemicals (2000), Annual Report 1999–2000, Ministry of Chemicals and Fertilizers, Government of India, New Delhi.
Economic Times (2005), ‘Glenmark takes over SA sales company’, December 27.
Economic Times (2005), ‘Sun Pharma buys Able Labs of US’, December 26.
Economic Times (2006), ‘Jubilant in 5-yr contract with Eli Lilly’, January 04.
Economic Times (2006), ‘Ranbaxy acquires Belgian co’, Friday, March 31.
Equitymaster (2003), ‘Pharma outsourcing: The next big thing’, August 25.
Express Pharma (2005), ‘AstraZeneca, Nicholas Piramal clinch R&D pact’, 16–30 November.
Express Pharma (2005), ‘Dishman Pharma enters into an agreement with NU SCAAN, UK’, July 05.
Express Pharma (2005), ‘Ranbaxy acquires generic product portfolio from Efarmes’, June 16.
Fergerberg, J. (1987), ‘A Technology Gap Approach to Why Growth Rates Differ’, Research Policy, 16, pp. 87–99.
Financial Express (2003), ‘NPIL in Outsourcing Deal with Advanced Medical Optics’, Wednesday, December 10.
Financial Express (2004), ‘Nirma acquires Core Healthcare’, Friday, December 17.
Financial Express (2006), ‘Ranbaxy buys GSK generic biz’, Tuesday, March 28.
Fink, C. (2000), ‘How Stronger Patent Protection in India Might Affect the Behavior of Transnational Pharmaceutical Industries’, World Bank Policy Research Working Paper No. 2352.
Hindu (2003), ‘Ranbaxy to buy RPG (Aventis)’, Sunday, Dec 14.
Hindu (2004) ‘Sun Pharma ups stake in Caraco’, Wednesday, Mar 17.
Hindu (2005), ‘Shasun Chemicals pact with Codexis of U.S.’, Thursday, May 12.
Hindu Business Line (2001), ‘Dishman inks supply pact with Dutch co’, March 22.
Hindu Business Line (2001), ‘Sun Pharma: Buy’, Sunday, February 25.
Hindu Business Line (2002), ‘Ranbaxy arm buys production unit from US company’, Wednesday, July 24.
Hindu Business Line (2002), ‘Ranbaxy buys Veratide from P&G in Germany’, Friday, Jun 28.
Hindu Business Line (2002), ‘Ranbaxy to pick up 10% stake in Japanese co’, Friday, Sep 27.
Hindu Business Line (2002), ‘Ranbaxy: A dose of US’, Friday, January 11.
Hindu Business Line (2002), ‘Sun Pharma to hike Caraco stake to 50%’, Thursday, Oct 03.
Hindu Business Line (2004), ‘Glenmark acquires 2 FDA-approved products from Clonmel’, Tuesday, Aug 31.
Hindu Business Line (2004), ‘Glenmark acquires Brazilian firm for Rs 22 crore’, Saturday, Apr 03.
Hindu Business Line (2004), ‘NPIL inks deal with French firm for skincare products’, Jun 08.
Hindu Business Line (2004), ‘NPIL inks two custom mfg contracts’, November 04.
Hindu Business Line (2004), ‘Shasun, Eastman Chemical in tie-up — To make performance chemicals for pharma cos’, Wednesday, Jun 16.
Hindu Business Line (2004), ‘Sun Pharma to buy three brands from US co for $5.4 m’, Saturday, Sep 25.
Hindu Business Line (2005), ‘Glenmark acquires Argentine marketing firm Servycal’, Thursday, October 27.
Hindu Business Line (2005), ‘Glenmark acquires hormonal brand in Brazil for $4.6 m’, Friday, March 18.
Hindu Business Line (2005), ‘NPIL-Pfizer deal on animal health products’, Dec 27.
Hindu Business Line (2005), ‘Sun Pharma acquires Hungarian unit of US co’, Thursday, Aug 11.
Hindu Business Line (2006), ‘Shasun Chemicals net up 43 pc’, Saturday, Jan 21.
India Brand Equity Foundation (2004), ‘Pharma MNCs turn to India for cost management’, August 6.
India Infoline (2000), ‘Contract Manufacturing: Growth Engine for Indian Pharma Companies?’, August 16.
Kumar, N. and J. P. Pradhan (2003), ‘Economic Reforms, WTO and Indian Drugs and Pharmaceuticals Industry: Implications of Emerging Trends’, CMDR Monograph Series, No. 42, the Centre for Multidisciplinary Development Research, Dharwad, India.
Kumar, Nagesh (2003), ‘Intellectual Property Rights, Technology and Economic Development: Experiences of Asian Countries’, Economic and Political Weekly, January 18, pp. 209–226.
Lalitha, N (2002), ‘Indian Pharmaceutical Industry in WTO Regime, A SWOT Analysis’, Economic and Political Weekly, Vol.XXXVIII, No.34.
Lanjouw, J. O. (1998), ‘The Introduction of Pharmaceutical Product Patents in India: Heartless Exploitation of the Poor and Suffering?’, NBER Working Paper No. 6366.
Lupin Laboratories (2004), ‘Lupin enters into an alliance with Baxter for Ceftriaxone’, Press Release, Feb 28.
Lupin Laboratories (2004), ‘Lupin Enters into Collaboration to Promote Zymar to Pediatricians in the U.S.’, Press Release, March 29.
Lupin Laboratories (2006), ‘Lupin’s US Subsidiary Enters Into Collaboration to Promote Atopiclair™’, Press Release, March 03.
Lupin Laboratories (2006), ‘Lupin-Aspen sign MOU for Anti-TB Joint Venture’, Press Release, February 27.
Nicholas Piramal (2003), ‘Nicholas Piramal to market Minrad's new generation inhalation anesthetics in 10 countries’, January 31.
Oraganization of Pharmaceutical Producers of India, (2004), ‘Indian Pharmaceutical Industry- Fact Sheet– 2004’, available at http://www.indiaoppi.com/keystat.htm
Organization of Pharmaceutical Producers of India (2004), ‘Indian Pharmaceutical Industry- Fact Sheet– 2004’, available at http://www.indiaoppi.com/keystat.htm
Pharmaceutical Policy 2002, Press Information Bureau Releases, February 15, 2002, available at http://www.nppaindia.nic.in/ceiling/policy.htm
Pradhan, J. P. (2002a), ‘FDI Spillovers and Local Productivity Growth: Evidence from Indian Pharmaceutical Industry’, Artha Vijnana, Vol XLIV, No. 3–4.
Pradhan, J.P. (2002b), ‘Liberalization, Firm Size and R&D performance: A Firm Level Study of Indian Pharmaceutical Industry’, Journal of Indian School of Political Economy, Vol. 14, No. 4.
Pradhan, J.P. (2006), ‘Strengthening Intellectual Property Rights Globally: Impact on India’s Pharmaceutical Exports’, Singapore Economic Review, (forthcoming).
Ranabxy (2002), ‘Ranbaxy And Adcock Ingram Form Joint Venture In South Africa To Market Anti-Retroviral Products’, , Press Release, October 16.
Ranabxy (2002), ‘Ranbaxy and Schwarz Pharma Sign a Deal to Develop New Drug to Treat Benign Prostate Hyperplasia’, Press Release, June 27.
Ranabxy (2002), ‘Ranbaxy obtains exclusive marketing rights for nifedipine-xl from Penwest, USA also collaborates on developing other controlled release products’, Press Release, February 25.
Ranabxy (2003), ‘GSK and Ranbaxy to collaborate on drug discovery and development’, Press Release, October 22.
Ranabxy (2003), ‘Ranbaxy and Mallinckrodt Baker Inc, USA, enter into a marketing alliance in India’, Press Release, July 02.
Ranabxy (2003), ‘Ranbaxy enters into collaborative research with ‘Medicines for Malaria Venture’ (MMV), Geneva, for the development of Anti-Malarial Drug’, Press Release, May 19.
Ranabxy (2004), ‘Ranbaxy and Atrix sign a licensing agreement for prostate cancer drug in India’, Press Release, June 24.
Ranbaxy (2004), Annual Report 2004.
Stoneman, P. (1983), The Economic Analysis of Technology Policy, Oxford University Press.
Verspangen, B. (1991), ‘A New Empirical Approach to Catching Up or Falling Behind’, Structural Change and Economic Dynamics, 2, pp. 359–380.
Watal, J. (1996), ‘Introducing Product Patent in the Indian Pharmaceutical Sector: Implications for Prices and Welfare’, World Competition, 20 (2), pp. 5–21.
Wockhardt (2004,) Annual Report 2004.
Zimmerman, R. and J. Pesta (2001), ‘Drug Industry, AIDS Community is Jolted by Cipla AIDS-Drug Offer’, Wall Street Journal - February 8, 2001.